<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">According to the above evidence, remdesivir has been used to treat SARS-CoV-2, and in vitro experiments showed that remdesivir has a good inhibitory effect on SARS-CoV-2, with an EC
 <sub>50</sub> of 0.77 μM [
 <xref ref-type="bibr" rid="CR39">39</xref>]. Recently, the first COVID-19 patient in the United States was treated with remdesivir on the 7th day of hospitalization, and their clinical symptoms were improved significantly [
 <xref ref-type="bibr" rid="CR61">61</xref>]. At present, a phase three clinical trial of remdesivir for COVID-19 has been officially launched in China, and a total of 761 patients are planned to be enrolled in the study, which will be randomized, double-blind and placebo-controlled [
 <xref ref-type="bibr" rid="CR62">62</xref>].
</p>
